ICU Medical Inc. (ICUI) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, ICUI scores 59 out of 100 (letter grade C-, verdict "Roarable Hold — Cautious Neutral"). Across the five pillars: Fundamental Cash Engine scores 9/20 (ROIC 1%; FCF yield 2.18%), the weakest reading in the framework and a signal that the business currently generates little return on capital relative to its size. Whale/13F Flow scores 15/20 (institutional accumulation and options positioning), the strongest pillar, suggesting institutional interest has been constructive. Insider Conviction scores 10/20 (SEC Form 4 and Congressional PTR cluster flow), indicating only moderate insider signal. Macro Regime Fit scores 10/20 (Beta 1.0; sector sensitivity), meaning the stock tracks the broader market without a distinct defensive or offensive advantage per this framework. Forensic Balance Sheet scores 15/20 (Altman Z 2.5; Piotroski F 8/9; Debt/Equity 0.6), a comparatively solid reading on balance-sheet health.

For a prospective investor, the upside case rests on the institutional flow and balance-sheet strength pillars, while the valuation tradeoff is significant: the low ROIC and FCF yield combined with an EV/EBITDA of 46.6 imply the market is pricing in substantial future improvement that the trailing cash generation does not yet show. The rating's "Hold" verdict reflects that balance between constructive forensic health and weak current cash returns.

ICU Medical Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Per the profile, the company's market capitalization is $4.2B. The source data does not detail its specific products, customer base, or revenue model beyond sector and industry classification. Gross margin is reported at 36.8% per the market data.

Per the SEC financials, revenue declined from $2382.0M in FY 2024 to $2231.3M in FY 2025, while operating income was roughly flat and net income moved to $0.7M from a loss of $-117.7M. Operating margin is 1.9% and net margin is 0% per the market data, with ROIC at 1%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 8/9, and Debt/Equity is 0.6. Reported debt declined from $1531.9M to $1265.9M across the two most recent periods, while FCF fell from $124.7M to $91.8M.

Per the recent news feed, the headlines reference two FDA Class II recalls ("Is ICU Medical (ICUI) Undervalued After Two FDA Class II Recalls?"), which is the most material risk item in the wire. Other items include a Zacks industry outlook mention, a Simply Wall St piece on infusion growth (flagged as a GREEN catalyst), a TradingView Q2 sector comparison, and a Stock Traders Daily note on momentum shifts. Most items are tagged YELLOW (market wire) with one GREEN (catalyst). The Butterfly graph reports no supply-chain links and no proprietary signals.

• What is the scope and resolution status of the two FDA Class II recalls referenced in the news wire, and what revenue exposure do they carry?
• Why did reported net income swing from $-117.7M in FY 2024 to $0.7M in FY 2025, and what drove the change?
• What are the reported EPS, cash balance, and TTM earnings, which are absent from the source data?
• Does the GREEN infusion-growth catalyst translate into measurable margin or revenue expansion?
• How does the 46.6 EV/EBITDA multiple compare with peers, given no analyst or peer data is provided?